Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of “Moderate Buy” by Brokerages
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) have received an average recommendation of “Moderate Buy” from the seventeen research firms that are presently covering the company, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and fourteen have assigned a buy recommendation to the company. The average twelve-month price […]
More Stories
49Ers Sign LB Warner to Massive Extension
By John Riggolizzo Fred Warner has officially become the highest-paid inside linebacker in the NFL. The San Francisco 49ers signed...
US New Home Sales Unexpectedly Surge in April to 3-Year High
By Andrew Moran New home sales in the United States unexpectedly surged in April to the highest level in more...
Americans Are Expected to Set Travel Record on Memorial Day Weekend
By Jacob Burg Between trips along the nation’s highways and byways or flights high in the sky, Americans are determined...
Trump Signs Order Telling Federal Agencies to Engage in ‘Gold Standard’ Science
By Zachary Stieber President Donald Trump on May 23 signed an order that directs federal agencies to engage in what...
DOGE Says It Completed ‘Major Cleanup’ of Social Security Records
By Jack Phillips The Department of Government Efficiency (DOGE) said in a statement on Thursday that its staff have completed...
US and China Resume Trade Talks After Geneva Meeting
By Aldgra Fredly China’s communist regime said on May 23 that it would continue talks with the U.S. government to...